VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Dec. 6, 2006) - ALDA Pharmaceuticals Corp. (TSX VENTUREAPH) ("ALDA") announces that it has retained Rhone Alternative Marketing Partners ("RAMP") of Geneva, Switzerland to raise funds in Europe to undertake the testing and registration of the topical therapeutic applications of ALDA's T36® technology. Dr. Terrance Owen, President & CEO, states, "We are extremely pleased to be working with such an eminent group as RAMP. We look forward to securing the financing that is required for ALDA to prepare its therapeutic products for the market."
